COVID-19 and the pharma industry.

It’s a contentious relationship, but we all have our socially responsible part to play.

We’ve all been affected by the coronavirus pandemic, and while markets are down and social distancing is the new normal, the world looks to science to find a solution.

By partnering with a global #pharma company working towards the common antivirus goal, it’s possible to achieve great things, including:

★ Performing bioanalytical testing of blood samples from COVID-19 positive patients in record time

★ Implementing, developing & validating analytical methods for the testing of raw materials in readiness for mass-producing a COVID-19 vaccine on never-before-seen scale

★ Conducting bioequivalence studies with novel neuroprotective drugs which show significant anti-inflammatory properties

QUINTA-ANALYTICA have been quietly but successfully playing their part by utilizing specialist skill sets and equipment in-house to assist multiple partners in their quest to find a vaccine, or source APIs that have become as scarce as feathers on a fish!

Working with key research projects Quinta are proud to be doing their part in the collective effort to rid the world of the most impactful issue ever seen.

Additional News

  • 5 srpna 2025

    Preclinical Bioanalysis That Accelerates Clinical Entry

    How fit-for-purpose and GLP-compliant bioanalysis can streamline your path to IND and CTA approvals.

  • 22 června 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 června 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.